Actinogen Medical
Logotype for Actinogen Medical Limited

Actinogen Medical (ACW) investor relations material

Actinogen Medical Study result summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Actinogen Medical Limited
Study result summary19 Nov, 2026

Trial design

  • XanaMIA was a randomized, double-blind, placebo-controlled 36-week trial of Xanamem 10 mg daily in 247 patients with mild-to-moderate Alzheimer’s disease; primary endpoint was CDR-SB change at Week 36.

  • Mean age was 75.4 years in the Xanamem group and 73.4 in the placebo group; the prespecified over-75 subgroup comprised ~50% of participants.

Efficacy findings

  • Overall, Xanamem showed a 0.10-point CDR-SB benefit at Week 36, which was not statistically significant (p=0.65).

  • Interim Week 24 analysis showed a 0.58-point benefit (p=0.03) in 88 participants; this was not sustained in the final analysis.

  • In the prespecified over-75 subgroup, Xanamem showed 30% slowing of progression, with a 0.39-point CDR-SB difference at Week 36 (p=0.22).

  • Among participants over 75, 40% on Xanamem had no CDR-SB progression versus 22% on placebo; the stable-or-improved response difference was significant (p=0.02).

  • Cognition and daily-function endpoints numerically favored Xanamem; no clear signal was seen in the younger-than-75 subgroup.

Safety and open-label extension

  • Xanamem was well tolerated over 36 weeks, with no serious adverse events attributed to treatment.

  • The first 29 open-label participants reaching 24 weeks of active treatment showed mean CDR-SB disease stabilization; preliminary trends showed reductions in GFAP and neurofilament light, but not p-tau.

  • An update is expected in Q1 CY2027 when ~100 participants have completed at least 24 weeks of open-label treatment.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Actinogen Medical earnings date

Logotype for Actinogen Medical Limited
AGM 202629 Nov, 2026
Actinogen Medical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Actinogen Medical earnings date

Logotype for Actinogen Medical Limited
AGM 202629 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Actinogen Medical Limited is a biotechnology company focused on the development of treatments for cognitive impairment and neurodegenerative diseases. The company’s primary research centers on therapies that target neurological pathways involved in conditions such as Alzheimer's disease and other forms of cognitive decline. Actinogen Medical leverages its proprietary drug development platform to create innovative solutions aimed at improving brain health and cognitive function. Actinogen Medical Limited is headquartered in Sydney, Australia, and its shares are listed on the ASX.